# A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

> **NCT05130060** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Colon Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Microsatellite Stable Colon Carcinoma
- Metastatic Microsatellite Stable Colorectal Carcinoma
- Metastatic Rectal Adenocarcinoma
- Microsatellite Stable Rectal Carcinoma
- Stage IV Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Colorectal Cancer Peptide Vaccine PolyPEPI1018
- **DRUG:** Trifluridine and Tipiracil Hydrochloride

## Key facts

- **NCT ID:** NCT05130060
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-10
- **Primary completion:** 2023-06-11
- **Final completion:** 2023-06-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130060, "A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05130060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*